Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
August 26, 2025
Guest User
The Commissioner’s National Priority Voucher ...

08/26/2025

-

On June 17th, 2025, the U.S. Food and Drug Administration (FDA) introduced its Commissioner’s National Priority Voucher (CNVP) pilot program to accelerate development of select drugs or biologics from companies that are supporting U.S. national interests and are aligned with U.S. national health priorities.

The Commissioner’s National Priority Voucher Pilot Program
August 11, 2025
Guest User
EMA Releases Guidelines on Inclusion of ...

08/11/2025

-

On June 4, 2025 the European Medicines Agency (EMA) posted a guideline titled: ICH E21 Guideline on inclusion of pregnant and breastfeeding individuals in clinical trials. Individuals who are pregnant or breastfeeding make up a significant portion of the world’s population, however, the European Union (EU) reports that less than 0.4% of clinical trials currently submitted to the EU include pregnant people and only 0.1% include lactating individuals. This guideline highlights the importance of including these individuals as well as the steps that should be taken in order to ensure their safety during a trial.  

EMA Releases Guidelines on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials
July 29, 2025
Guest User
Inadequate Source Documentation Results in FDA ...

07/29/2025

-

On May 29th, 2024, the US Food and Drug Administration (FDA) issued a Form FDA 483 and subsequent warning letter to a Principal Investigator (PI) as the result of objectionable conditions found during an inspection under the Bioresearch Monitoring Program (BIMO).

Inadequate Source Documentation Results in FDA Warning Letter
July 15, 2025
Guest User
Progress Update on the BsUFA III Regulatory ...

07/14/2025

-

In January 2025, the US Food and Drug Administration (FDA) posted a progress update video about the third iteration of the Biosimilar User Fee Act (BsUFA III) regulatory science pilot program by sharing results from recent studies, outcomes of round table discussions, and upcoming milestones.

Progress Update on the BsUFA III Regulatory Science Pilot Program
July 8, 2025
Guest User
New Final Guidance Q&A on RRAs

07/08/2025

-

In June 2025, The US Food and Drug Administration (FDA) released the final guidance titled; “Conducting Remote Regulatory Assessments Questions and Answers” to facilitate understanding about what a remote regulatory assessment (RRA) is expected from establishments when the FDA initiates or requests an RRA.

New Final Guidance Q&A on RRAs
Sandra Sather
November 19, 2015

2016 Edition of International Compilation of Human Research Standards Now Available

Sandra Sather
November 19, 2015

11/19/2015

The Office for Human Research Protections (OHRP) has released the 2016 edition of the International Compilation of Human Research Standards. View them here and learn how they will affect our indstry!

Sandra Sather
September 21, 2015

Nov 19-20 iiBIG: Clinical Teamwork Conference Announced

Sandra Sather
September 21, 2015

09/21/2015

Join SAM Sather, and Clinical Pathways at the 2nd Annual Clinical Study Teamwork conference to be held November 19-20, 2015 in Cary, NC!

Sandra Sather
September 14, 2015

Our Work is for Their Future - 16th Annual ACRP RTP Chapter Fall Conference

Sandra Sather
September 14, 2015

09/14/2015

Join subject matter expert SAM Sather at the 16th Annual ACRP RTP Chapter Fall Conference October 8th and 9th. SAM is presenting Friday October 9th a 75 minute session on the "New FDA Informed Consent Draft Guidance: electronic Informed Consent and Information Sheet".

Sandra Sather
September 10, 2015

Re-envisioning the Federal Policy for the Protection of Human Subjects

Sandra Sather
September 10, 2015

09/10/2015

A major change is underway regarding the Federal Policy for the Protection of Human Subjects! Take a look here and find out how it could affect our industry.

Sandra Sather
September 7, 2015

New ICH E6 Good Clinical Practice (GCP) Updates!

Sandra Sather
September 7, 2015

09/07/2015

The long awaited new revisions to the ICH E6 GCP guidelines have been released! The European Medicines Agency (EMA) posted a version(s) for review.

Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 24

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.